Viability of Normal Mononuclear Cell Samples Exposed to Depsipeptide Expressed as Percentage of Viability Versus Control ± Standard Deviation
| Depsipeptide Concentration (μmol/L) . | 4-h Exposure Then Washed and Viability Assessed at 4 d . | 1-d Exposure Then Washed and Viability Assessed at 4 d . | 4-d Exposure and Then Viability Assessed at 4 d . |
|---|---|---|---|
| 0.0001 | 102.1 ± 4.8 | 100.8 ± 2.4 | 92.3 ± 10.2 |
| 0.00033 | 103.4 ± 8.5 | 99.5 ± 16.1 | 89.2 ± 13.6 |
| 0.001 | 102.8 ± 8.4 | 89.2 ± 14.3 | 67.7 ± 4.9 |
| 0.01 | 81.8 ± 10.5 | 66.7 ± 8.1 | 53.3 ± 4.3 |
| 0.1 | 59.8 ± 4.2 | 59.8 ± 6.1 | 45.9 ± 10.0 |
| 1 | 49.1 ± 6.8 | 47.5 ± 4.1 | 39.3 ± 9.0 |
| 3.3 | 47.6 ± 7.3 | 39.6 ± 3.7 | 31.5 ± 6.7 |
| 10 | 40.0 ± 6.8 | 21.6 ± 6.7 | 12.8 ± 4.9 |
| 33 | 5.7 ± 2.2 | 5.1 ± 3.2 | 5.7 ± 4.6 |
| Depsipeptide Concentration (μmol/L) . | 4-h Exposure Then Washed and Viability Assessed at 4 d . | 1-d Exposure Then Washed and Viability Assessed at 4 d . | 4-d Exposure and Then Viability Assessed at 4 d . |
|---|---|---|---|
| 0.0001 | 102.1 ± 4.8 | 100.8 ± 2.4 | 92.3 ± 10.2 |
| 0.00033 | 103.4 ± 8.5 | 99.5 ± 16.1 | 89.2 ± 13.6 |
| 0.001 | 102.8 ± 8.4 | 89.2 ± 14.3 | 67.7 ± 4.9 |
| 0.01 | 81.8 ± 10.5 | 66.7 ± 8.1 | 53.3 ± 4.3 |
| 0.1 | 59.8 ± 4.2 | 59.8 ± 6.1 | 45.9 ± 10.0 |
| 1 | 49.1 ± 6.8 | 47.5 ± 4.1 | 39.3 ± 9.0 |
| 3.3 | 47.6 ± 7.3 | 39.6 ± 3.7 | 31.5 ± 6.7 |
| 10 | 40.0 ± 6.8 | 21.6 ± 6.7 | 12.8 ± 4.9 |
| 33 | 5.7 ± 2.2 | 5.1 ± 3.2 | 5.7 ± 4.6 |